U.S. Stem Cell, Inc.
DelistedCIK 1388319fmd_1GQXPJ76GM05ZDSK86VK23GSQNServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Jan 01, 2000 to Dec 31, 2022, 61 periods
Latest annual · FY2022
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (2)
- Net income
- (3)
Latest quarter · Q4 FY2022
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (0)
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2019 to FY2022
- -70.1%
- Revenue, 5 yearsFY2017 to FY2022
- -56.9%
- Net income, 5 yearsFY2017 to FY2022
- n/m
U.S. Stem Cell, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2022 | FY2021 | Change | Source |
|---|---|---|---|---|
| Revenue | $82,049 | $200,749 | -59.1% | 10-K 2023-04-14 · proof |
| Gross profit | $58,282 | $148,719 | -60.8% | 10-K 2023-04-14 · proof |
| Operating income | -$1.7 million | -$2.1 million | 10-K 2023-04-14 · proof | |
| Net income | -$2.9 million | -$3.3 million | 10-K 2023-04-14 · proof | |
| Cash from operating activities | -$304,852 | -$1.1 million | 10-K 2023-04-14 · proof | |
| Total assets | $68,039 | $50,999 | +33.4% | 10-K 2023-04-14 · proof |
| Total liabilities | $14.8 million | $12.8 million | +15.6% | 10-K 2023-04-14 · proof |
| Cash and cash equivalents | $5,133 | $39,393 | -87% | 10-K 2023-04-14 · proof |
- What was U.S. Stem Cell, Inc.'s revenue in fiscal 2022?
- U.S. Stem Cell, Inc. reported revenue of $82,049 for fiscal 2022 (the year ended Dec 31, 2022), against $200,749 the year before (-59.1%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was U.S. Stem Cell, Inc.'s gross profit in fiscal 2022?
- U.S. Stem Cell, Inc. reported gross profit of $58,282 for fiscal 2022 (the year ended Dec 31, 2022), against $148,719 the year before (-60.8%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was U.S. Stem Cell, Inc.'s operating income in fiscal 2022?
- U.S. Stem Cell, Inc. reported operating income of -$1.7 million for fiscal 2022 (the year ended Dec 31, 2022), against -$2.1 million the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was U.S. Stem Cell, Inc.'s net income in fiscal 2022?
- U.S. Stem Cell, Inc. reported net income of -$2.9 million for fiscal 2022 (the year ended Dec 31, 2022), against -$3.3 million the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What was U.S. Stem Cell, Inc.'s cash from operating activities in fiscal 2022?
- U.S. Stem Cell, Inc. reported cash from operating activities of -$304,852 for fiscal 2022 (the year ended Dec 31, 2022), against -$1.1 million the year before. Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What are U.S. Stem Cell, Inc.'s total assets?
- As of Dec 31, 2022, U.S. Stem Cell, Inc. reported total assets of $68,039, against $50,999 a year earlier (+33.4%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What are U.S. Stem Cell, Inc.'s total liabilities?
- As of Dec 31, 2022, U.S. Stem Cell, Inc. reported total liabilities of $14.8 million, against $12.8 million a year earlier (+15.6%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
- What are U.S. Stem Cell, Inc.'s cash and cash equivalents?
- As of Dec 31, 2022, U.S. Stem Cell, Inc. reported cash and cash equivalents of $5,133, against $39,393 a year earlier (-87%). Source: the 10-K filed with the SEC on Apr 14, 2023. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1388319&period_type=annual&limit=5"Information only, not investment advice.